DK0524968T3 - Heterovesikulære lipidvesikler - Google Patents

Heterovesikulære lipidvesikler

Info

Publication number
DK0524968T3
DK0524968T3 DK91906733.0T DK91906733T DK0524968T3 DK 0524968 T3 DK0524968 T3 DK 0524968T3 DK 91906733 T DK91906733 T DK 91906733T DK 0524968 T3 DK0524968 T3 DK 0524968T3
Authority
DK
Denmark
Prior art keywords
emulsion
lipid vesicles
vial
composition
heterovesicular
Prior art date
Application number
DK91906733.0T
Other languages
Danish (da)
English (en)
Inventor
Sinil Kim
Original Assignee
Depotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depotech Corp filed Critical Depotech Corp
Application granted granted Critical
Publication of DK0524968T3 publication Critical patent/DK0524968T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
DK91906733.0T 1990-03-21 1991-03-20 Heterovesikulære lipidvesikler DK0524968T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49684690A 1990-03-21 1990-03-21

Publications (1)

Publication Number Publication Date
DK0524968T3 true DK0524968T3 (da) 1995-07-31

Family

ID=23974416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91906733.0T DK0524968T3 (da) 1990-03-21 1991-03-20 Heterovesikulære lipidvesikler

Country Status (20)

Country Link
EP (1) EP0524968B1 (fr)
JP (1) JP3461000B2 (fr)
KR (1) KR100203223B1 (fr)
CN (1) CN1053101C (fr)
AT (1) ATE123412T1 (fr)
AU (1) AU655177B2 (fr)
CA (1) CA2078666C (fr)
DE (1) DE69110281T2 (fr)
DK (1) DK0524968T3 (fr)
ES (1) ES2073164T3 (fr)
FI (1) FI104464B (fr)
IE (1) IE62772B1 (fr)
IL (1) IL97615A (fr)
NO (1) NO304576B1 (fr)
NZ (1) NZ237464A (fr)
PT (1) PT97101B (fr)
RU (1) RU2120795C1 (fr)
SA (1) SA93130496B1 (fr)
WO (1) WO1991014445A1 (fr)
ZA (1) ZA911974B (fr)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3278273B2 (ja) * 1993-12-17 2002-04-30 キヤノン株式会社 薬剤徐放性カプセル
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
JP4275741B2 (ja) 1996-12-13 2009-06-10 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 血小板由来増殖因子タンパク質の分析および分離
US5985214A (en) 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
EP1014946B1 (fr) 1997-09-18 2010-04-07 Pacira Pharmaceuticals, Inc. Compositions anesthesiques de liposomes a liberation prolongee
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
EP1030652B1 (fr) 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production de liposomes multivesiculaires
WO1999036544A2 (fr) 1998-01-14 1999-07-22 Chiron S.P.A. Antigenes du $i(neisseria meningitidis)
EP1645631B1 (fr) 1998-05-01 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
JP2002527066A (ja) 1998-10-15 2002-08-27 カイロン コーポレイション 転移性乳癌および結腸癌調節遺伝子
ATE408695T1 (de) 1998-12-16 2008-10-15 Novartis Vaccines & Diagnostic Menschliche cyclin-abhängige kinase (hpnqalre)
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
WO2000066741A2 (fr) 1999-04-30 2000-11-09 Chiron S.P.A. Antigenes de neisseria conserves
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
PT2275551E (pt) 1999-10-29 2015-06-29 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
JP2003516731A (ja) 1999-11-18 2003-05-20 カイロン コーポレイション ヒトｆｇｆ−２１遺伝子および遺伝子発現産物
MXPA02006962A (es) 2000-01-17 2002-12-13 Chiron Spa Vacuna de vesicula de membrana exterior que comprende proteinas de membrana exterior de neisseria meningitidis serogrupo b.
EP2075255A1 (fr) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Gène FGF-23 humain et produits d'expression de gènes
EP1950297A2 (fr) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions et procédés de traitement de maladie néoplastique utilisant la chimiothérapie et des sensibilisateurs à rayonnement
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1370684B1 (fr) 2000-06-15 2008-05-28 Novartis Vaccines and Diagnostics, Inc. Polynucleotides lies au cancer du colon
CA2881568C (fr) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Acides nucleiques et proteines derives des groupes de streptocoques a et b
US7776523B2 (en) 2000-12-07 2010-08-17 Novartis Vaccines And Diagnostics, Inc. Endogenous retroviruses up-regulated in prostate cancer
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081639A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 et ses utilisations diagnostiques et therapeutiques
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
US7309783B2 (en) 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
EP1404713A4 (fr) 2001-05-24 2004-09-22 Human Dna Technology Inc Nouvel analogue du facteur de croissance des keratinocytes-2 du follicule pileux
CA2465953A1 (fr) 2001-11-09 2003-05-15 Georgetown University Nouveaux isoformes de l'inhibiteur de la croissance de cellules endotheliales vasculaires
EP2335724A1 (fr) 2001-12-12 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Immunisation contre la Chlamydia trachomatis
SG148035A1 (en) 2002-01-08 2008-12-31 Novartis Vaccines & Diagnostic Gene products differentially expressed in cancerous breast cells and their methods of use
JP2005520543A (ja) 2002-03-21 2005-07-14 サイグレス ディスカバリー， インコーポレイテッド 癌における新規組成物および方法
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
WO2004046177A2 (fr) 2002-11-15 2004-06-03 Chiron Srl Proteines de surface inattendues sur le meningocoque
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1575517B1 (fr) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2004074321A2 (fr) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Nouveaux cibles therapeutiques du recepteur de couplage a la proteine g dans le cancer
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
DE602004030535D1 (de) 2003-02-19 2011-01-27 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070042184A1 (en) 2003-08-22 2007-02-22 Danisco A/S Microcapsules
WO2005062955A2 (fr) 2003-12-23 2005-07-14 Rinat Neuroscience Corp. Anticorps anti-trkc agonistes et procedes d'utilisation
KR101222281B1 (ko) 2004-03-29 2013-01-28 가르파마 컴퍼니 리미티드 신규 갈렉틴 9 개변체 단백질 및 그 용도
ES2338344T3 (es) 2004-04-07 2010-05-06 Rinat Neuroscience Corporation Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
EP1789593B1 (fr) 2004-07-09 2017-03-15 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Formes solubles de glycoproteine g des virus hendra
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
US7807165B2 (en) 2004-07-30 2010-10-05 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588295C (fr) 2004-11-23 2013-10-22 Neuromolecular Pharmaceuticals, Inc. Procede et composition pour administrer un antagoniste du recepteur de nmda a un sujet
WO2006058236A2 (fr) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition et methode pour traiter des affections neurologiques
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
ES2385045T3 (es) 2005-02-18 2012-07-17 Novartis Vaccines And Diagnostics, Inc. Inmunógenos de Escherichia coli uropatogénica
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
US20090220495A1 (en) 2005-04-07 2009-09-03 Abdallah Fanidi Cancer Related Genes (PRLR)
EP1865981A2 (fr) 2005-04-07 2007-12-19 Chiron Corporation Cacna1e dans le diagnostic, la detection et le traitement du cancer
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CA2615615A1 (fr) 2005-07-22 2007-02-01 Y's Therapeutics Co., Ltd. Anticorps anti-cd26 et methodes d'utilisation de ces derniers
AP2008004467A0 (en) 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
RU2461572C2 (ru) 2006-06-07 2012-09-20 Биоэллаенс К.В. Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения
EP2035035A2 (fr) 2006-06-09 2009-03-18 Novartis AG Compositions immunogenes pour streptococcus agalactiae
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
WO2008116032A1 (fr) 2007-03-21 2008-09-25 Effat Emamian Compositions et procédés d'inhibition de la croissance des cellules tumorales
EP2155777A2 (fr) 2007-04-10 2010-02-24 The Administrators of the Tulane Educational Fund Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102216329A (zh) 2007-12-17 2011-10-12 辉瑞有限公司 间质性膀胱炎的治疗
EP2245063B1 (fr) 2007-12-18 2015-08-26 BioAlliance C.V. Anticorps reconnaissant un épitope contenant des glucides sur cd-43 et cea exprimés sur des cellules cancéreuses et leurs procédés d'utilisation
WO2009126306A2 (fr) 2008-04-10 2009-10-15 Cell Signaling Technology, Inc. Compositions et procédés pour la détection des mutations d’egfr en cas de cancer
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
EP2403526B1 (fr) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Antigènes de chlamydia
WO2010118243A2 (fr) 2009-04-08 2010-10-14 Genentech, Inc. Utilisation d'antagonistes de il-27 pour traiter le lupus
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
CA2767536A1 (fr) 2009-07-07 2011-01-13 Novartis Ag Immunogenes d' escherichia coli conserves
PL2464658T3 (pl) 2009-07-16 2015-03-31 Novartis Ag Immunogeny z Escherichia coli o zniesionej toksyczności
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
TWI552760B (zh) 2010-02-24 2016-10-11 雷那特神經科學股份有限公司 拮抗劑抗－ｉｌ－７受體抗體及方法
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
CN102844332B (zh) 2010-03-11 2015-08-19 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (fr) 2010-04-22 2011-10-27 Genentech, Inc. Utilisation d'antagonistes d'il-27 pour traiter une maladie intestinale inflammatoire
US9770414B2 (en) * 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
WO2012015758A2 (fr) 2010-07-30 2012-02-02 Saint Louis University Méthodes de traitement de la douleur
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (fr) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions et procédés pour traiter le cancer
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
WO2013093693A1 (fr) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
WO2014008263A2 (fr) 2012-07-02 2014-01-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Paramyxovirus et méthodes d'utilisation
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
BR112015010722A2 (pt) 2012-11-09 2017-08-22 Pfizer Anticorpos específicos de fator de crescimento derivado de plaquetas de isoforma b e composições e usos dos mesmos
CA2906624A1 (fr) 2013-03-15 2014-09-25 Dyax Corp. Anticorps anti-kallicreine plasmatique
JP2016520058A (ja) 2013-05-07 2016-07-11 ライナット ニューロサイエンス コーポレイション 抗グルカゴン受容体抗体およびその使用方法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
BR112016002008B1 (pt) 2013-08-02 2021-06-22 Pfizer Inc. Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
WO2015109212A1 (fr) 2014-01-17 2015-07-23 Pfizer Inc. Anticorps anti-il-2 et compositions et utilisations de ceux-ci
MX2016012188A (es) 2014-03-21 2017-04-27 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
WO2015168474A1 (fr) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Protéines de fusion pour le traitement du cancer et procédés associés
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
MY196625A (en) 2015-04-13 2023-04-23 Pfizer Therapeutic Antibodies and Their Uses
CA2993026A1 (fr) 2015-07-21 2017-01-26 Dyax Corp. Inhibiteur d'anticorps monoclonal du facteur xiia
WO2017015334A1 (fr) 2015-07-21 2017-01-26 Saint Louis University Compositions et méthodes pour diagnostiquer et traiter l'infertilité associée à l'endométriose
EP3325010B1 (fr) 2015-07-23 2023-06-21 The Regents of The University of California Anticorps anti-facteur de coagulation xia et leurs utilisations
NZ739871A (en) 2015-08-19 2022-05-27 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
CN113896789A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
JP6661319B2 (ja) * 2015-09-28 2020-03-11 小林製薬株式会社 リポソーム
CA2946113A1 (fr) 2015-10-23 2017-04-23 Pfizer Inc. Anticorps anti-il-2 et leurs compositions et methodes d'utilisation
WO2017075037A1 (fr) 2015-10-27 2017-05-04 Scholar Rock, Inc. Facteurs de croissance amorcés et leurs utilisations
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
EP3397253A1 (fr) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
TW201936640A (zh) 2016-01-21 2019-09-16 美商輝瑞股份有限公司 對表皮生長因子受體變異體ｉｉｉ具特異性之抗體類及彼等之用途
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
KR20190124753A (ko) 2017-03-03 2019-11-05 리나트 뉴로사이언스 코프. 항-gitr 항체 및 이의 사용 방법
JP7177076B2 (ja) 2017-03-16 2022-11-22 ファイザー・インク チロシン原栄養性
CA3059938A1 (fr) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Anticorps antagonistes du facteur d du complement et leurs conjugues
WO2018200885A1 (fr) 2017-04-26 2018-11-01 Neurocentria, Inc. Compositions de magnésium et méthodes d'utilisation
WO2018220584A1 (fr) 2017-06-02 2018-12-06 Pfizer Inc. Anticorps spécifiques à la flt3 et leurs utilisations
JP7034183B2 (ja) 2017-06-13 2022-03-11 ボストンジーン コーポレイション 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法
JP2020527558A (ja) 2017-07-13 2020-09-10 マサチューセッツ インスティテュート オブ テクノロジー シナプス機能を増強するためのｈｄａｃ２−ｓｐ３複合体の標的化
WO2019016784A1 (fr) 2017-07-21 2019-01-24 Universidade De Coimbra Anticorps anti-nucléoline
EP3692370A2 (fr) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles et procédés destinés à la thérapie personnalisée du cancer
CN112020518A (zh) 2018-02-01 2020-12-01 辉瑞公司 靶向cd70的嵌合抗原受体
US11377500B2 (en) 2018-02-01 2022-07-05 Pfizer Inc. Antibodies specific for CD70 and their uses
KR20200128116A (ko) 2018-02-28 2020-11-11 화이자 인코포레이티드 Il-15 변이체 및 이의 용도
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
MX2020012539A (es) 2018-05-23 2021-02-16 Pfizer Anticuerpos especificos para cd3 y sus usos.
US20210005284A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for nucleic acid data quality control
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3152623A1 (fr) 2019-10-11 2021-04-15 Richard D. Cummings Anticorps anti-tn et leurs utilisations
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (fr) 2020-04-08 2021-10-14 Pfizer Inc. Anticorps anti-gucy2c et leurs utilisations
WO2021224850A1 (fr) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Peptides masques et anticorps anti-ptk7 masqués les comprenant
EP4182346A1 (fr) 2020-07-17 2023-05-24 Pfizer Inc. Anticorps thérapeutiques et leurs utilisations
US20230287455A1 (en) 2020-07-30 2023-09-14 Pfizer Inc. Cells Having Gene Duplications and Uses Thereof
AU2021338361A1 (en) 2020-09-03 2023-04-06 Chen, Irvin S.Y Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2022232615A1 (fr) 2021-04-29 2022-11-03 Bostongene Corporation Techniques d'apprentissage machine pour estimer une expression de cellules tumorales dans un tissu tumoral complexe
WO2023012627A1 (fr) 2021-08-02 2023-02-09 Pfizer Inc. Vecteurs d'expression améliorés et leurs utilisations
WO2023147177A1 (fr) 2022-01-31 2023-08-03 Bostongene Corporation Techniques d'apprentissage automatique pour cytométrie
WO2023148598A1 (fr) 2022-02-02 2023-08-10 Pfizer Inc. Prototrophie cystéinique
WO2024015561A1 (fr) 2022-07-15 2024-01-18 Bostongene Corporation Techniques de détection d'une déficience de recombinaison homologue (hrd)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
CH624011A5 (fr) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CA1237671A (fr) * 1983-08-01 1988-06-07 Michael W. Fountain Augmentation de l'activite pharmaceutique
EP0199362A3 (fr) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology Système et dispositif pour la libération retardée et par à-coups de substances biologiquement actives
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes

Also Published As

Publication number Publication date
CN1055663A (zh) 1991-10-30
WO1991014445A1 (fr) 1991-10-03
FI104464B (fi) 2000-02-15
ATE123412T1 (de) 1995-06-15
JP3461000B2 (ja) 2003-10-27
ES2073164T3 (es) 1995-08-01
NZ237464A (en) 1995-02-24
PT97101A (pt) 1991-11-29
EP0524968A4 (en) 1993-03-24
NO923624L (no) 1992-09-17
EP0524968A1 (fr) 1993-02-03
KR100203223B1 (ko) 1999-06-15
NO923624D0 (no) 1992-09-17
DE69110281D1 (de) 1995-07-13
JPH05507680A (ja) 1993-11-04
CA2078666C (fr) 2001-10-02
DE69110281T2 (de) 1995-11-09
AU655177B2 (en) 1994-12-08
FI924193A (fi) 1992-09-18
ZA911974B (en) 1994-08-22
CA2078666A1 (fr) 1991-09-22
PT97101B (pt) 1998-08-31
EP0524968B1 (fr) 1995-06-07
IE910911A1 (en) 1991-09-25
IL97615A (en) 1995-06-29
IE62772B1 (en) 1995-02-22
SA93130496B1 (ar) 2004-08-14
NO304576B1 (no) 1999-01-18
IL97615A0 (en) 1992-06-21
FI924193A0 (fi) 1992-09-18
RU2120795C1 (ru) 1998-10-27
AU7580691A (en) 1991-10-21
CN1053101C (zh) 2000-06-07

Similar Documents

Publication Publication Date Title
DK0524968T3 (da) Heterovesikulære lipidvesikler
FI922151A0 (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
ATE82495T1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
ATE71303T1 (de) Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
DE3867866D1 (de) Liposomzubereitung und ihre herstellung.
SE8103843L (sv) Farmaceutisk mixtur
ATE20574T1 (de) Pulverfoermige mischung von lipiden und hydrophoben bestandteilen, verfahren zu deren herstellung, hydratierte lamellare lipide phasen und verfahren zur herstellung, pharmazeutische oder kosmetische mittel die hydratierte lamellare lipide phasen enthalten.
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
HK160995A (en) Complex compounds of bioflavonoids with phospholipids their preparation and use and pharmaceutical and cosmetic compositions containing them
HUT48455A (en) Process for producing stabilized pharmaceutical compositions containing dipeptide derivatives
KR900701174A (ko) 인지질-함유 조성물, 이의 제조방법 및 이의 약제학적 물질용 부형제로서의 용도
ES2085920T3 (es) Liposomas dirigidos y metodos de acoplamiento liposoma-proteina.
ES2042437T1 (es) Procedimiento de preparacion de una lipoproteina modificaa por incorporacion de una substancia activa lipofila.
DE3166084D1 (en) Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
PT79649B (en) Process for preparing pharmaceutical compositions for therapeutical treatment of rheumatic diseases containing oxicam derivatives and 1,2-diacylglycero-3-phosphocholine
FI810380L (fi) Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen
SE8302580L (sv) Substituerade iminoderivat av dihydrobensopyran och dihydrobensotiopyran och forfarande for deras framstellning
IL82925A0 (en) Tetrahydrobenzothiazoles,their preparation and pharmaceutical compositions containing them
SE8503447L (sv) Farmaceutiska och kosmetiska kompositioner, innehallande dihydroxi-1,8-fenyl-10-antron-9 som verksam bestandsdel, samt sett att framstella den verksamma foreningen
FR2595703B1 (fr) Nouveaux phospholipides, leur procede et les intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2363562A1 (fr) Nouveaux derives du 5-fluorouracile, utiles notamment comme agents anticancereux et leur procede de preparation
PT72247B (fr) Procede de preparation de nouveaux derives de l'amino-1 propanol-2 et leur application en therapeutique
DE3879709T2 (de) Platin-arzneimittel.